339 related articles for article (PubMed ID: 10847561)
1. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.
Pappolla MA; Chyan YJ; Poeggeler B; Frangione B; Wilson G; Ghiso J; Reiter RJ
J Neural Transm (Vienna); 2000; 107(2):203-31. PubMed ID: 10847561
[TBL] [Abstract][Full Text] [Related]
2. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism.
Reiter RJ; Cabrera J; Sainz RM; Mayo JC; Manchester LC; Tan DX
Ann N Y Acad Sci; 1999; 890():471-85. PubMed ID: 10668453
[TBL] [Abstract][Full Text] [Related]
3. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors.
Pappolla MA; Simovich MJ; Bryant-Thomas T; Chyan YJ; Poeggeler B; Dubocovich M; Bick R; Perry G; Cruz-Sanchez F; Smith MA
J Pineal Res; 2002 Apr; 32(3):135-42. PubMed ID: 12074096
[TBL] [Abstract][Full Text] [Related]
4. A new model for the pathophysiology of Alzheimer's disease. Aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin.
van Rensburg SJ; Daniels WM; Potocnik FC; van Zyl JM; Taljaard JJ; Emsley RA
S Afr Med J; 1997 Sep; 87(9):1111-5. PubMed ID: 9358827
[TBL] [Abstract][Full Text] [Related]
5. New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
López-Iglesias B; Pérez C; Morales-García JA; Alonso-Gil S; Pérez-Castillo A; Romero A; López MG; Villarroya M; Conde S; Rodríguez-Franco MI
J Med Chem; 2014 May; 57(9):3773-85. PubMed ID: 24738476
[TBL] [Abstract][Full Text] [Related]
6. Novel indole-based melatonin analogues: Evaluation of antioxidant activity and protective effect against amyloid β-induced damage.
Gurer-Orhan H; Karaaslan C; Ozcan S; Firuzi O; Tavakkoli M; Saso L; Suzen S
Bioorg Med Chem; 2016 Apr; 24(8):1658-64. PubMed ID: 26970662
[TBL] [Abstract][Full Text] [Related]
7. Role of melatonin in Alzheimer-like neurodegeneration.
Wang JZ; Wang ZF
Acta Pharmacol Sin; 2006 Jan; 27(1):41-9. PubMed ID: 16364209
[TBL] [Abstract][Full Text] [Related]
8. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease.
Reddy PH
J Neurochem; 2006 Jan; 96(1):1-13. PubMed ID: 16305625
[TBL] [Abstract][Full Text] [Related]
9. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system.
Reiter RJ; Acuña-Castroviejo D; Tan DX; Burkhardt S
Ann N Y Acad Sci; 2001 Jun; 939():200-15. PubMed ID: 11462772
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin.
Pappolla MA; Chyan YJ; Poeggeler B; Bozner P; Ghiso J; LeDoux SP; Wilson GL
J Pineal Res; 1999 Nov; 27(4):226-9. PubMed ID: 10551770
[TBL] [Abstract][Full Text] [Related]
11. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites.
Reiter RJ; Tan DX; Jou MJ; Korkmaz A; Manchester LC; Paredes SD
Neuro Endocrinol Lett; 2008 Aug; 29(4):391-8. PubMed ID: 18766165
[TBL] [Abstract][Full Text] [Related]
12. The oxidant/antioxidant network: role of melatonin.
Reiter RJ; Tan DX; Cabrera J; D'Arpa D; Sainz RM; Mayo JC; Ramos S
Biol Signals Recept; 1999; 8(1-2):56-63. PubMed ID: 10085463
[TBL] [Abstract][Full Text] [Related]
13. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants.
Reiter RJ; Tan DX; Allegra M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():3-8. PubMed ID: 12019343
[TBL] [Abstract][Full Text] [Related]
14. Melatonin: new places in therapy.
Maharaj DS; Glass BD; Daya S
Biosci Rep; 2007 Dec; 27(6):299-320. PubMed ID: 17828452
[TBL] [Abstract][Full Text] [Related]
15. Melatonin: an ancient molecule that makes oxygen metabolically tolerable.
Manchester LC; Coto-Montes A; Boga JA; Andersen LP; Zhou Z; Galano A; Vriend J; Tan DX; Reiter RJ
J Pineal Res; 2015 Nov; 59(4):403-19. PubMed ID: 26272235
[TBL] [Abstract][Full Text] [Related]
16. [Melatonin as an antioxidant].
Skrzydlewska E
Postepy Hig Med Dosw; 2001; 55(6):871-89. PubMed ID: 11875783
[TBL] [Abstract][Full Text] [Related]
17. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties.
Fernández-Bachiller MI; Pérez C; Campillo NE; Páez JA; González-Muñoz GC; Usán P; García-Palomero E; López MG; Villarroya M; García AG; Martínez A; Rodríguez-Franco MI
ChemMedChem; 2009 May; 4(5):828-41. PubMed ID: 19308922
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of melatonin in experimental models of Alzheimer disease.
Cheng Y; Feng Z; Zhang QZ; Zhang JT
Acta Pharmacol Sin; 2006 Feb; 27(2):129-39. PubMed ID: 16412260
[TBL] [Abstract][Full Text] [Related]
19. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease.
Miranda S; Opazo C; Larrondo LF; Muñoz FJ; Ruiz F; Leighton F; Inestrosa NC
Prog Neurobiol; 2000 Dec; 62(6):633-48. PubMed ID: 10880853
[TBL] [Abstract][Full Text] [Related]
20. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)].
Zatta P; Tognon G; Carampin P
J Pineal Res; 2003 Sep; 35(2):98-103. PubMed ID: 12887652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
